BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 22306898)

  • 1. Myeloid-derived suppressor cells in cancer patients: a clinical perspective.
    Montero AJ; Diaz-Montero CM; Kyriakopoulos CE; Bronte V; Mandruzzato S
    J Immunother; 2012; 35(2):107-15. PubMed ID: 22306898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
    Solito S; Bronte V; Mandruzzato S
    J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-derived suppressor cell heterogeneity in human cancers.
    Solito S; Marigo I; Pinton L; Damuzzo V; Mandruzzato S; Bronte V
    Ann N Y Acad Sci; 2014 Jun; 1319():47-65. PubMed ID: 24965257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cells contribute to oral cancer progression in 4NQO-treated mice.
    Chu M; Su YX; Wang L; Zhang TH; Liang YJ; Liang LZ; Liao GQ
    Oral Dis; 2012 Jan; 18(1):67-73. PubMed ID: 21883708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
    Fujimura T; Mahnke K; Enk AH
    J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients.
    Tobin RP; Davis D; Jordan KR; McCarter MD
    J Leukoc Biol; 2017 Aug; 102(2):381-391. PubMed ID: 28179538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-derived suppressor cells in cancer: recent progress and prospects.
    Khaled YS; Ammori BJ; Elkord E
    Immunol Cell Biol; 2013 Sep; 91(8):493-502. PubMed ID: 23797066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-derived suppressor cell role in tumor-related inflammation.
    Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
    Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.
    Ye XZ; Yu SC; Bian XW
    J Genet Genomics; 2010 Jul; 37(7):423-30. PubMed ID: 20659706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.
    Tadmor T; Attias D; Polliack A
    Br J Haematol; 2011 Jun; 153(5):557-67. PubMed ID: 21477210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
    Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
    J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells.
    Husain Z; Huang Y; Seth P; Sukhatme VP
    J Immunol; 2013 Aug; 191(3):1486-95. PubMed ID: 23817426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
    Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
    Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells.
    Hock BD; Mackenzie KA; Cross NB; Taylor KG; Currie MJ; Robinson BA; Simcock JW; McKenzie JL
    Nephrol Dial Transplant; 2012 Jan; 27(1):402-10. PubMed ID: 21617199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer.
    Kusmartsev S; Gabrilovich DI
    Cancer Metastasis Rev; 2006 Sep; 25(3):323-31. PubMed ID: 16983515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growing diversity and spectrum of action of myeloid-derived suppressor cells.
    Mantovani A
    Eur J Immunol; 2010 Dec; 40(12):3317-20. PubMed ID: 21110315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients.
    Jiang J; Guo W; Liang X
    Hum Immunol; 2014 Nov; 75(11):1128-37. PubMed ID: 25305034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cell heterogeneity and subset definition.
    Peranzoni E; Zilio S; Marigo I; Dolcetti L; Zanovello P; Mandruzzato S; Bronte V
    Curr Opin Immunol; 2010 Apr; 22(2):238-44. PubMed ID: 20171075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer.
    Katoh H; Watanabe M
    Mediators Inflamm; 2015; 2015():159269. PubMed ID: 26078490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Dysthe M; Parihar R
    Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.